Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds
Meeting ReportOncology - Basic: Basic Science

Radionuclide gene therapy with herpes simplex virus type 1 thymidine kinase and I-125 or I-131 labeled nucleoside analog

TaeSup Lee, JooHyun Kang, KS Woo, WeeSup Jung, Gi Jeong Cheon, ChangWoon Choi and SangMoo Lim
Journal of Nuclear Medicine May 2009, 50 (supplement 2) 1599;
TaeSup Lee
1KIRAMS, Molecular Imaging Research Center, Seoul, South Korea
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
JooHyun Kang
1KIRAMS, Molecular Imaging Research Center, Seoul, South Korea
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KS Woo
1KIRAMS, Molecular Imaging Research Center, Seoul, South Korea
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
WeeSup Jung
1KIRAMS, Molecular Imaging Research Center, Seoul, South Korea
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gi Jeong Cheon
1KIRAMS, Molecular Imaging Research Center, Seoul, South Korea
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ChangWoon Choi
1KIRAMS, Molecular Imaging Research Center, Seoul, South Korea
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SangMoo Lim
1KIRAMS, Molecular Imaging Research Center, Seoul, South Korea
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

1599

Objectives The herpes simplex virus type 1 thymidine kinase (HSV1-tk) enzyme selectively phosphorylate and accumulate several nucleoside analogs including 5’-Iodovinyl deoxyuridine (IVDU). This study aims to evaluate whether I-125 or I-131 labeled IVDU has different biological effect in radionuclide gene therapy using HSV1-tk and IVDU.

Methods MCA and MCA-TK cells, retrovirally transduced with HSV1-tk, were used. 125I- or 131I-labeled IVDU uptakes per cell were determined at 4 h incubation in 0, 1, 10 and 100 μCi doses. Radiotherapeutic efficacy of 125I- or 131IVDU (0, 1, 10, 100 μCi) treated MCA and MCA-TK cells for 4 h incubation was evaluated by in vitro clonogenic assay.

Results 125IVDU significantly accumulated in MCA-TK cells compared to MCA cells.125IVDU or 131IVDU uptakes in MCA cells were minimal at each radioactivity dose. 125IVDU and 131IVDU uptakes in MCA-TK cells were 9.11±0.03 pCi/cell and 9.19±0.10 pCi/cell, respectively, at 100 mCi dose after 4 h incubation. Survival rate (%) of MCA-TK was markedly decreased as radioactivity dose dependent manner. Survival rate of 125IVDU treated MCA-TK(57.02±7.09, 29.88±6.66 and 4.86±4.02) was significantly lower than that of 131IVDU treated MCA-TK (68.13±7.64, 33.75±2.54 and 20.08±3.65) at 1, 10 and 100 μCi doses.

Conclusions I-125 and I-131 labeled IVDU selectively accumulated and killed HSV1-tk expressing tumor cells. Radionuclide HSV1-tk gene therapy with 125IVDU might be better therapeutic strategy than that with 131IVDU, and further studies is needed for biological mechanism.

  • © 2009 by Society of Nuclear Medicine
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 50, Issue supplement 2
May 2009
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Radionuclide gene therapy with herpes simplex virus type 1 thymidine kinase and I-125 or I-131 labeled nucleoside analog
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Radionuclide gene therapy with herpes simplex virus type 1 thymidine kinase and I-125 or I-131 labeled nucleoside analog
TaeSup Lee, JooHyun Kang, KS Woo, WeeSup Jung, Gi Jeong Cheon, ChangWoon Choi, SangMoo Lim
Journal of Nuclear Medicine May 2009, 50 (supplement 2) 1599;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Radionuclide gene therapy with herpes simplex virus type 1 thymidine kinase and I-125 or I-131 labeled nucleoside analog
TaeSup Lee, JooHyun Kang, KS Woo, WeeSup Jung, Gi Jeong Cheon, ChangWoon Choi, SangMoo Lim
Journal of Nuclear Medicine May 2009, 50 (supplement 2) 1599;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Oncology - Basic: Basic Science

  • Dicer substrate siRNA-mediated silencing of human sodium iodide symporter (hNIS) gene in hNIS-expressing cell lines
  • Small animal PET imaging of recombinant single chain fragment variable of anti-TAG-72 humanized antibody in colon cancer xenograft model
  • Enhancing anti-CD20 directed radioimmunotherapy. Preliminary studies using lenalidomide-accelerated internalization
Show more Oncology - Basic: Basic Science

Basic Science Posters

  • [131I] ICF01012, a potential agent for targeted radionuclide therapy of melanoma
  • In vitro and in vivo characterization of a new somatostatin (SST) DOTA-conjugated analog
  • The change of F-18 FDG and H-3 PCV uptakes after transduction of micro RNA for hexokinase II and HSV1-sr39 gene in cancer cells
Show more Basic Science Posters

Similar Articles

SNMMI

© 2023 Journal of Nuclear Medicine

Powered by HighWire